Transformative Cardiac Solutions
Accelerate your clinical research with AliveCor BioPharma’s comprehensive cardiac monitoring solutions from protocol to post marketing.
Discover how to choose the right sensor partner with our free eBook.
AliveCor BioPharma’s cardiac monitoring solutions utilize innovative technology to instantly capture ECG data, enabling real-time, accurate insights for faster and more informed decision- making, all while ensuring your clinical trial remains compliant with the latest industry guidelines.
- Patient-centric, flexible trial design that leverages decentralized elements, diversity, and digital health technology
- Improved focus on cardiac safety, a top reason for drug withdrawal from the trials and the market 1
- Accurate, clinically validated solutions that are pivotal for delivering quality clinical trial ECG data and alleviating common cardiac monitoring challenges
Innovative, Customized Cardiac Monitoring Solutions
Harness the power of globally trusted cardiac monitoring technology designed to seamlessly adapt to your unique needs. Our full service management solution, elevates the patient experience and enhances adherence to ensure your success.
- From Protocol to Post Marketing
- Onsite or Remote
- Across Phases and Therapeutic Areas
Let AliveCor BioPharma help support every phase of your clinical trials, from initial protocol to post-market analysis with our award-winning cardiac monitoring solution.
Our Easy, Three-Step Customized Cardiac Monitoring Solution
Benefit from a fully-managed solution that integrates trusted ECG data, captured instantly and AI-driven software for faster decision-making and instant, traceable insights.
Capture
FDA-cleared medical-grade ECG devices capture 6-lead or 12-lead heart data, either remotely or onsite.
Kardia AI
Record & Review
Our mobile applications for healthcare providers and patients instantly record and deliver ECG data to medical professionals.
Software & Algoritms
Analyze & Manage
ECG data is uploaded to our HIPAA-compliant portal and can be shared with partner platforms to be analyzed and interpreted.
SDK/API
AliveCor in Product Life Cycles Today
Personalized Workflows Drive Therapy Adoption
To better market a new S1P moderator drug for Ulcerative Colitis, Pharma leader successfully implemented AliveCor solutions to remove treatment barriers
The program enrolled more than 2,200 gastroenterologists, integrated fast, portable ECGs, and built a board-certified cardiologist overread program.
- Increased US therapy adoption and differentiated from future competitors
- Improved patient, physician, and staff experience
Custom Program Removes Prescription Barriers
A custom strategy for a global pharmaceutical leader with a new metastatic cancer drug enrolled more than 800 oncologists.
Through performing more than 9,600 in-office and remote ECGs over 18 months, oncologists found greater confidence in therapy selection.
- Increased worldwide adoption of drug with superior clinical profile
- Improved patient and oncologist experience while streamlining workflows
Validated and Trusted Globally
5.4M+
lifetime users
250+
million ECGs recorded
25+
countries with studies powered by our ECG solutions
200+
clinical publications validating clinical utility
Featured Insights
Gain confidence in your clinical trials by exploring insights from industry-leading experts. Browse blogs and articles.
Why Portable 6-Lead Devices Are the Future of Cardiac Monitoring in Clinical Trials
QT determinations are essential in clinical trials, but collecting them is challenging. Discover how the KardiaMobile® 6L alleviates these challenges for more flexible and patient-centric trials.
Remote Monitoring Boosts Decentralized Trials
PharmExec.com | Decentralized trials are known to have positive effects, but sponsors have concerns about how to monitor patients well. Remote patient monitoring (RPM) solutions, like those from AliveCor, are changing this paradigm. The benefits that decentralized trials offer patients and sponsors are evident. Yet, decentralized trials are still lacking.
JAMA Study Shows KardiaMobile 6L Could Reduce the Need to Perform a 12-Lead ECG In Resource Limited Settings
At a QTc interval threshold of 500 milliseconds, the KardiaMobile 6-lead device had a high negative predictive value of 99.8% and was an effective triage test. This validation is pivotal for sponsors aiming to deliver quality data while alleviating common cardiac monitoring challenges.
"AliveCor's technology equips our sponsors and CROs to collect essential heart data and QT
information, which is critical in drug development. It supports a greater patient
experience and confidence which translates into greater success in our trials. Working
with AliveCor, we meet the real-world needs of patients and caregivers, driving tangible
improvements in healthcare outcomes and research efficacy."
-
Matt Noble
SVP, Head of Patient Cloud
Medidata
"Their digital ECG solution enables trial design flexibility for follow-up visits, or even full decentralization, without impacting data quality.
It’s also very easy to use, making it very appealing to trial participants. [It] dramatically expands our ability to collect ECG data from outpatients in clinical trials or even in clinical practice."
-
Robert Kleiman
Chief Scientific & Regulatory Advisor, Cardiac Safety
Clario
Choose AliveCor for your clinical trials.
Connect with us for a custom integration strategy that sets your research apart.
At AliveCor, data security is a top priority. We uphold high standards of protection and compliance for our customers and continually improve our governance strategies as we grow to ensure secure technology services. Learn more about our certifications on our security page.
1. Mamoshina, Polina et al. Cell Reports Medicine, Volume 2, Issue 3, 100216
2. Metcalfe JZ, Economou T, Naufal F, et al. Validation of a Handheld 6-Lead Device for QT Interval Monitoring in Resource-Limited Settings. JAMA Netw Open. 2024